Compare Bank of India Flexi Cap Fund vs ICICI Prudential Focused Equity Fund
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 1.98 | 1.69 |
NAV | ₹34.86 | ₹97.25 |
Fund Started | 10 Jun 2020 | 15 Apr 2009 |
Fund Size | ₹2243.99 Cr | ₹14568.53 Cr |
Exit Load | Exit load of 1%, if redeemed within 3 months. | Exit load of 1% if redeemed within 1 year |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹1000
₹100
Expense Ratio
1.98
1.69
NAV
₹34.86
₹97.25
Fund Started
10 Jun 2020
15 Apr 2009
Fund Size
₹2243.99 Cr
₹14568.53 Cr
Exit Load
Exit load of 1%, if redeemed within 3 months.
Exit load of 1% if redeemed within 1 year
1 Year | 2.47% | 18.84% |
3 Year | 20.63% | 23.13% |
5 Year | 19.69% | 20.17% |
1 Year
2.47%
18.84%
3 Year
20.63%
23.13%
5 Year
19.69%
20.17%
Equity | 99.39% | 97.46% |
Cash | 0.26% | 1.87% |
Equity
99.39%
97.46%
Cash
0.26%
1.87%
Top 10 Holdings |
|
|
Top 10 Holdings
Vedanta Ltd. | 5.77% |
State Bank of India | 5.71% |
ICICI Bank Ltd. | 3.89% |
Lloyds Metals & Energy Ltd. | 3.53% |
Bharti Airtel Ltd. | 3.40% |
Hindustan Aeronautics Ltd. | 3.32% |
ITC Ltd. | 3.09% |
HDFC Bank Ltd. | 2.92% |
CreditAccess Grameen Ltd. | 2.80% |
UNO Minda Ltd. | 2.58% |
ICICI Bank Ltd. | 7.60% |
HDFC Bank Ltd. | 5.57% |
Infosys Ltd. | 4.83% |
Axis Bank Ltd. | 4.58% |
Sun Pharmaceutical Industries Ltd. | 4.52% |
Godrej Consumer Products Ltd. | 3.92% |
Titan Company Ltd. | 3.90% |
NTPC Ltd. | 3.73% |
Info Edge (India) Ltd. | 3.71% |
Britannia Industries Ltd. | 3.70% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity-related securities across various market capitalisation. | The scheme seeks to generate capital appreciation by investing in a concentrated portfolio of equity and equity related securities of up to 30 companies across market capitalization i.e. focus on multicap. |
Launch Date | 10 Jun 2020 | 15 Apr 2009 |
Description
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity-related securities across various market capitalisation.
The scheme seeks to generate capital appreciation by investing in a concentrated portfolio of equity and equity related securities of up to 30 companies across market capitalization i.e. focus on multicap.
Launch Date
10 Jun 2020
15 Apr 2009